| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro.
Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.
Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of 6.8% over the prior year.
Med Device net sales were $41.8 million, a decrease of 3.8% compared to $43.4 million in the prior-year period.
AngioDynamics also announced a stock repurchase program of up to $15.0 million.
Also Read: AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement.
“We view 2025 as an inflection point in the trajectory of our business…The increased scale of our Med Tech business, in combination with the optimization of our Med Device business, will allow us to begin to see increasing leverage as we exit the year. Operationally, we will continue to work through the transition of our manufacturing model to reduce overhead costs and improve margins in 2026 and beyond,” commented Jim Clemmer, President and CEO.
Guidance: AngioDynamics expects its fiscal year 2025 net sales of $282 million-$288 million, up 4.2%–6.4% year over year from 2024 pro forma revenue of $270.7 million and compared to the consensus of $287.68 million.
The outlook includes Med Tech net sales to increase 10%-12%, and Med Device net sales are expected to grow 1%-3%.
Gross margin is expected to be approximately 52% to 53% for fiscal year 2025. Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million a year ago.
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of $0.38-$0.42, compared to fiscal 2024 pro forma adjusted EPS loss of $0.45 and consensus loss of $0.49.
Price Action: ANGO shares are up 25.6% at $7.445 at last check Tuesday.
Read Next:
Posted In: ANGO
